References
- DrukerBJGuilhotFO’BrienSGFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med2006355232408241717151364
- WeisbergEManleyPWCowan-JacobSWHochhausAGriffinJDSecond generation inhibitors of BCR-ABL for the treatment of imatinib-resistant CMLNature Rev Cancer20077534535617457302
- Bristol-Myers Squibb CompanySprycel (dasatinib) prescribing informationPrinceton, NJBristol-Myers Squibb Company2008
- Novartis PharmaceuticalsTasigna (nilotinib) prescribing informationFlorham Park, NJNovartis Pharmaceuticals2007
- KoledinMDuricDMilovancevABijelovicMBarosBPleural effusions of malignant etiology: diagnostics, treatment and quality of lifeArch Oncol20019137
- Quintas-CardamaAKantarjianHO’BrienSPleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failureJ Clin Oncol200725253908391417761974
- Quintas-CardamaAKantarjianHMMundenRPleural effusion in patients (pts) with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failure (abstract). ASH Annual MeetingBlood20061:108112164
- IngenixNational Fee Analyzer: Charge data for evaluating fees nationallyEden Prairie, MNIngenix2006
- IngenixOutpatient billing expertEden Prairie, MNIngenix2006
- PutnamJBJrWalshGLSwisherSGOutpatient management of malignant pleural effusion by a chronic indwelling pleural catheterAnn Thorac Surg200069236937510735665
- GirardiLNGinsbergRJBurtMEPericardiocentesis and intrapericardial sclerosis: effective therapy for malignant pericardial effusionsAnn Thorac Surg1997645142214279386714
- Thomson HealthcareRed BookMontvale, NJThomson Healthcare2008
- ShahNPKantarjianHMKimDWIntermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaJ Clin Oncol200826193204321218541900